Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bronstein, Gewirtz & Grossman, LLC Notifies CareDx, Inc. (CDNA) Shareholders of Class Action and Encourages Investors to Contact the Firm

CDNA

NEW YORK, May 31, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired CareDx securities between February 24, 2021, and May 5, 2022, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/cdna.

Bronstein, Gewirtz & Grossman, LLC

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that throughout the Class Period, Defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue, including: (i) pushing protocols for surveillance of organ rejection through inaccurate marketing materials and in violation of Medicare standards; (ii) offering extravagant inducements or kickbacks to physicians and other providers; and (iii) improperly bundling expensive testing services with other blood tests as part of the RemoTraC service. These practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny and rendered the Company's testing services revenue and demand reported throughout the Class Period artificially inflated. As a result, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/cdna or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in CareDx you have until July 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bronstein-gewirtz--grossman-llc-notifies-caredx-inc-cdna-shareholders-of-class-action-and-encourages-investors-to-contact-the-firm-301556946.html

SOURCE Bronstein, Gewirtz & Grossman, LLC



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today